Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.

Ki-Tae HwangEun-Kyu KimSung Hoo JungEun Sook LeeSeung Il KimSeokwon LeeHeung Kyu ParkJongjin KimSohee OhYoung A Kimnull null

Published in: Breast cancer research and treatment (2018)

Tamoxifen therapy group showed superior prognosis than the no-tamoxifen therapy group. Its prognostic influence was only effective for luminal A subtype. Patients with luminal A subtype showed higher survival rate than those with TN subtype. Active tamoxifen therapy is recommended for DCIS patients with luminal A subtype, and routine tests for ER, PR, and HER2 should be considered for DCIS.

Keyphrases

estrogen receptor
breast cancer cells
positive breast cancer
stem cells
clinical practice
young adults
bone marrow